Abstract
Background: We examined the associations between muscular strength, markers of overall and central adiposity, and cancer mortality in men.
Methods: A prospective cohort study including 8,677 men ages 20 to 82 years followed from 1980 to 2003. Participants were enrolled in The Aerobics Centre Longitudinal Study, the Cooper Institute in Dallas, Texas. Muscular strength was quantified by combining 1-repetition maximal measures for leg and bench presses. Adiposity was assessed by body mass index (BMI), percent body fat, and waist circumference.
Results: Cancer death rates per 10,000 person-years adjusted for age and examination year were 17.5, 11.0, and 10.3 across incremental thirds of muscular strength (P = 0.001); 10.9, 13.4, and 20.1 across BMI groups of 18.5-24.9, 25.0-29.9, and ≥30 kg/m2, respectively (P = 0.008); 11.6 and 17.5 for normal (<25%) and high percent body fat (≥25%), respectively (P = 0.006); and 12.2 and 16.7 for normal (≤102 cm) and high waist circumference (>102 cm), respectively (P = 0.06). After adjusting for additional potential confounders, hazard ratios (95% confidence intervals) were 1.00 (reference), 0.65 (0.47-0.90), and 0.61 (0.44-0.85) across incremental thirds of muscular strength, respectively (P = 0.003 for linear trend). Further adjustment for BMI, percent body fat, waist circumference, or cardiorespiratory fitness had little effect on the association. The associations of BMI, percent body fat, or waist circumference with cancer mortality did not persist after further adjusting for muscular strength (all P ≥ 0.1).
Conclusions: Higher levels of muscular strength are associated with lower cancer mortality risk in men, independent of clinically established measures of overall and central adiposity, and other potential confounders. (Cancer Epidemiol Biomarkers Prev 2009;18(5):1468–76)
Introduction
Cancer is one of the leading causes of death for North American as well as for European men, accounting for ∼285,000 and 850,000 of deaths annually, respectively (1, 2). Lifestyle-related factors associated with cancer mortality include smoking and poor diet. More recently, it has been shown that overall and central obesity also increases the risk of cancer (3-5). Another important lifestyle factor is the level of physical activity (6, 7). The IARC estimated in 2002 that up to one third of several types of cancers could be attributed to excess of body fat and a sedentary lifestyle (8). A dose-response relationship for several cancers has been reported, such that engaging in longer exercise sessions, or exercising at higher intensities or for more years, is associated with greater reductions in the risk of cancer development (8).
There is increasing evidence highlighting the beneficial effects of muscular strength in the prevention of chronic diseases, as well as in the performance of the activities of daily life (9). Resistance-type physical activities are major determinants of muscular strength and are currently recommended by the most influential health organizations, such as the American Heart Association and the American Cancer Society, for improving both health and fitness (10-13).
The prospective association between muscular strength and cancer mortality has been examined in several studies (14-17), with inconsistent findings. These studies assessed muscular strength via a handgrip test, which provides information derived from only a small muscle group. Assessing additional muscle groups should provide a better overall index of muscular strength, especially when measured in large muscle groups. In addition, none of these studies accounted for cardiorespiratory fitness, which has been shown to be a strong predictor of cancer mortality (18-25). We have shown that muscular strength measured in large muscle groups from the upper and lower body is inversely and independently associated with all-cause (26, 27) and cancer (27) mortality in men, even after adjusting for cardiorespiratory fitness.
Data from The Aerobics Centre Longitudinal Study (ACLS) showed that higher levels of cardiorespiratory fitness are associated with lower cancer mortality risk in men, independent of overall and central adiposity measures, such as body mass index [BMI, weight (kg) / height (m)2], percent body fat, and waist circumference (20). From a public health perspective, it is important to understand whether higher levels of muscular strength may counteract the negative consequences ascribed to adiposity. Studies examining the independent and joint associations among muscular strength, several established clinical measures of overall and central adiposity, and cancer mortality are scarce. Therefore, we examined these associations in a cohort of middle-aged men enrolled in the ACLS.
Materials and Methods
Study Population
Between 1980 and 1989, 10,265 men ages 20 to 82 years received a comprehensive medical examination and muscular strength tests at The Cooper Clinic in Dallas, Texas, United States, and were enrolled in the ACLS. Participants were predominantly European Americans, well educated, and belonged to middle to upper socioeconomic strata. Detailed information regarding the study population has been published previously (19, 28). Participants came to the clinic for periodic preventive health examinations and for counseling regarding diet, exercise, and other lifestyle factors associated with increased risk of chronic disease. Participants thus were volunteers (i.e., were not paid for participation). Many were sent by their employers for the examination, some were referred by their doctors, and others were self-referred.
Participants performed a maximal graded treadmill test to assess their cardiorespiratory fitness and had complete measures of height and weight (from which BMI was computed), percent body fat, and waist circumference. Participants were not included in the present study if, at baseline, they were either younger than 20 years or older than 90 years (n = 96); they did not achieve at least 85% of aged-predicted maximal heart rate (220 − age) during the treadmill test (n = 671); they had an abnormal resting or exercise electrocardiogram (ref. 29; n = 581); they reported history of myocardial infarction (n = 51), stroke (n = 6), or cancer (n = 55); or they were underweight (BMI <18.5 kg/m2; n = 128). These criteria resulted in 8,677 asymptomatic men ages 20 to 82 years, who were followed up from the date of their baseline examination until their date of death, or December 31, 2003. Participants provided written consent to participate in the follow-up study, and The Cooper Institute Institutional Review Board approved the study annually.
Clinical Data
Participants completed a comprehensive health evaluation that included self-reported personal and family health history, anthropometry, a standardized medical examination by a physician, fasting blood chemistry assessment, muscular strength tests, and a maximal graded treadmill exercise test. BMI was computed from measured weight and height (kg/m2). Percent body fat was assessed with hydrostatic weighing, the sum of seven skinfolds, or both, following standardized protocols (30). Detailed description of our hydrodensitometry procedures has been published elsewhere (31). Waist circumference was measured level with the umbilicus. Adiposity exposure groups were based on standard clinical definitions for BMI (normal weight: 18.5-24.9 kg/m2, overweight: 25.0-29.9 kg/m2, obese: 30.0 kg/m2 or higher); percent body fat (normal: <25%; obese: ≥25%; ref. 31); and waist circumference (normal: ≤102.0 cm; abdominal obesity: >102.0 cm).
Blood pressure was measured with standard auscultatory methods after the participant had been seated for 5 min. Systolic and diastolic blood pressures were recorded as the first and fifth Korotkof sounds, respectively. Concentrations of total and high density lipoprotein cholesterol, triglycerides, and glucose were determined in the Cooper Clinic clinical chemistry laboratory, which participates in and meets the quality control standards of the Centers for Disease Control and Prevention Lipid Standardization Program. Baseline medical conditions, such as previous myocardial infarction, stroke, hypertension, diabetes, and hypercholesterolemia, were defined as a history of physician diagnosis, measured phenotypes that met clinical thresholds for a specific condition, or when appropriate, the combination of both methods. Smoking habits (current smoker or not) and alcohol intake (number of drinks per week) were obtained from a standardized questionnaire.
Cardiorespiratory fitness was assessed by a maximal treadmill test using a modified Balke protocol (32), as previously described (19, 31). The mean (SD) percentage of age-predicted maximal heart rate achieved during exercise was 101.6 (6.2), which indicates that most participants achieved a maximal effort. The exercise duration on this protocol is highly correlated with measured maximal oxygen uptake (r = 0.92; ref. 33) and was used for the analyses (in minutes). To standardize the interpretation of exercise test performance, maximal metabolic equivalents (1 metabolic equivalent = 3.5 mL oxygen uptake/kg/min) were also estimated based on the final treadmill speed and grade (34). Cardiorespiratory fitness was dichotomized as unfit (low) and fit (high) corresponding to the lower 20% and the upper 80%, respectively, of the age-specific distribution of treadmill exercise duration in the overall ACLS population (31, 35-39).
We assessed muscular strength in the upper and lower body following a standardized strength testing protocol using variable resistance weight machines (Universal Equipment, Cedar Rapids, IA; refs. 40, 41). Upper body strength was assessed with a one-repetition maximum supine bench press, and lower body strength was assessed with a one-repetition maximum seated leg press. Initial loads (weights) were 70% of body weight for the bench press and 100% of body weight for the leg press. Increments of ∼2 to 4 kg were added until maximal effort was achieved for each lift, usually after five trials or less. Participants were allowed to rest (∼1-2 min) between trials. All participants were able to lift the initial load at least once. Participants were instructed on the proper breathing and lifting form for each movement. The intraclass correlation coefficient for one-repetition bench and leg press was 0.90 and 0.83, respectively, in a subgroup of 246 men who underwent two muscular strength assessments within a 1-year period (40). We computed a muscular strength score by combining the standardized values of bench and leg press (27). Each of these variables was standardized as follows: standardized value = (value − mean) / SD. The score was calculated separately for each age group (20-29, 30-39, 40-49, 50-59, and ≥60 years). The score for muscular strength was calculated as the mean of the two standardized scores (bench and leg presses). For analysis, we used thirds of the age-group–specific composite strength score.
Mortality Surveillance
Vital status was ascertained using the National Death Index and using death certificates from states in which participant death occurred. More than 95% of mortality follow-up is complete by these methods. The National Death Index has been shown to be an accurate method of ascertaining deaths in observational studies, with high sensitivity (96%) and specificity (100%; ref. 42). Cancer deaths were identified using the International Classification of Diseases, Ninth Revision (codes 140-208), for deaths occurring before 1999, and Tenth Revision (codes C00-C97) for deaths during 1999 to 2003. Cancers of the digestive and gastrointestinal (hereafter called digestive) system were identified using ICD-9/10 codes 150-159/C15-C26. For neoplasm of lymphoid, hematologic, and related tissues, ICD-9/10 codes 201.0-205.9 and 238.6/C81.0-C96 were used. For cancer in specific sites, the following ICD-9/10 codes were used: colon, 153/C18; rectum, 154/C19-C21; pancreas, 157/C25; lung, 162.2-163.0/C34; and prostate, 186/C61.
Statistical Analyses
The follow-up interval was computed from the date of a participant's baseline examination until the date of death for decedents, or until December 31, 2003, for survivors. Descriptive statistics summarized baseline characteristics by muscular strength fitness levels. Groups were compared using χ2 analysis (for categorical variables such as current smoker and hypertension) and general linear models with Bonferonni post hoc comparison tests (for continuous variables such as age and BMI). Cox proportional hazard models were used to estimate hazard ratios (HR), 95% confidence intervals (95% CI), and cancer mortality rates (deaths per 10,000 person-years of follow-up) according to exposure categories. Multivariate analyses included the following covariates: age (years), examination year, smoking status (current smoker or not), alcohol intake (≥5 drinks/wk or not), cardiorespiratory fitness (entered as a continuous variable, in minutes), and baseline medical conditions (presence or absence of hypertension, diabetes, or hypercholesterolemia). The proportional hazards assumption was examined by comparing the cumulative hazard plots grouped on exposure; no appreciable violations were noted. Tests of linear trends in mortality rates and risk estimates across exposure categories were computed using ordinal scoring for muscular strength thirds, BMI, percent body fat, and waist circumference groups. Models were also fitted with strength squared to assess nonlinearity.
Finally, we examined the joint associations of muscular strength and adiposity exposures with cancer mortality, as well as the joint associations of muscular strength and cardiorespiratory fitness with cancer mortality. We assessed the interaction among exposure groups using likelihood ratio tests of nested models. We calculated two-sided P values and we considered those <0.05 as significant. Analyses were done using SAS statistical software, version 9.1 (SAS, Inc.).
Results
During an average follow-up of 18.8 years and 163,128 person-years of exposure, 211 cancer deaths occurred. Baseline characteristics of the overall cohort according to muscular strength categories are presented in Table 1. With the exception of alcohol intake, each of the other baseline characteristics was significantly (P < 0.05) associated with categories of muscular strength. There was a direct gradient of treadmill test duration across increasing thirds of muscular strength (P < 0.001).
Baseline characteristics according to thirds of muscular strength, Aerobics Center Longitudinal Study, 1980 to 2003
Characteristic . | All (n = 8,677) . | Muscular strength thirds . | . | . | . | |||||
---|---|---|---|---|---|---|---|---|---|---|
. | . | Lowest (n = 2,892) . | Middle (n = 2,894) . | Upper (n = 2,891) . | P for linear trend . | |||||
Age, mean (SD), y | 42.7 (9.5) | 43.3 (9.5) | 42.7 (9.4) | 42.2 (9.7) | <0.0001 | |||||
BMI, mean (SD), kg/m2 | 25.8 (3.5) | 26.9 (4.2) | 25.5 (3.0) | 25.1 (2.7) | <0.0001 | |||||
Waist circumference, mean (SD), cm | 92.7 (10.1) | 97.5 (10.9) | 92.0 (8.8) | 88.6 (8.3) | <0.0001 | |||||
Percent body fat, mean (SD) | 20.3 (6.2) | 23.6 (5.9) | 20.1 (5.3) | 17.1 (5.5) | <0.0001 | |||||
Maximal METs, mean (SD) | 12.5 (2.5) | 11.5 (2.3) | 12.5 (2.3) | 13.4 (2.4) | <0.0001 | |||||
Treadmill time, mean (SD), min | 19.7 (4.9) | 17.7 (4.8) | 19.7 (4.6) | 21.6 (4.5) | <0.0001 | |||||
Bench press, mean (SD) | ||||||||||
kg | 71.5 (17.4) | 61.6 (12.1) | 69.6 (12.6) | 83.3 (19.0) | <0.0001 | |||||
kg/kg of body weight | 0.9 (0.2) | 0.7 (0.1) | 0.9 (0.1) | 1.1 (0.2) | <0.0001 | |||||
Leg press, mean (SD) | ||||||||||
kg | 136.7 (27.0) | 124.8 (24.7) | 135.5 (23.4) | 149.9 (26.5) | <0.0001 | |||||
kg/kg of body weight | 1.7 (0.3) | 1.4 (0.2) | 1.7 (0.2) | 1.9 (0.3) | <0.0001 | |||||
Lipids, mean (SD), mg/dL | ||||||||||
Total cholesterol | 211 (44) | 214 (41) | 212 (51) | 207 (40) | <0.0001 | |||||
High-density lipoprotein cholesterol | 46 (12) | 45 (12) | 46 (12) | 47 (12) | <0.0001 | |||||
Triglycerides | 130 (106) | 142 (105) | 131 (123) | 117 (85) | <0.0001 | |||||
Fasting blood glucose, mean (SD), mg/dL | 100 (14) | 101 (17) | 99 (13) | 98 (11) | <0.0001 | |||||
Blood pressure, mean (SD), mm Hg | ||||||||||
Systolic | 119 (13) | 120 (13) | 118 (12) | 119 (13) | <0.0001 | |||||
Diastolic | 79 (9) | 80 (9) | 79 (9) | 79 (9) | <0.0001 | |||||
Current smoker, n (%) | 1,313 (15.1) | 492 (17.0) | 455 (15.7) | 366 (12.7) | <0.0001 | |||||
Alcohol intake (≥5 drinks/wk), n (%) | 4,300 (49.6) | 1,431 (49.5) | 1,446 (50.0) | 1,423 (49.2) | 0.84 | |||||
Sedentary*, n (%) | 1,725 (19.9) | 746 (25.8) | 574 (19.8) | 405 (14.0) | <0.0001 | |||||
Baseline medical conditions,† n (%) | ||||||||||
Hypercholesterolemia | 1,875 (21.6) | 687 (23.8) | 632 (21.8) | 556 (19.2) | <0.0001 | |||||
Diabetes mellitus | 208 (2.4) | 100 (3.5) | 49 (1.7) | 59 (2.0) | 0.0005 | |||||
Hypertension | 2,166 (25.0) | 848 (29.3) | 688 (23.8) | 630 (21.8) | <0.0001 | |||||
Cardiovascular disease | 111 (1.3) | 49 (1.7) | 33 (1.1) | 29 (1.0) | 0.02 |
Characteristic . | All (n = 8,677) . | Muscular strength thirds . | . | . | . | |||||
---|---|---|---|---|---|---|---|---|---|---|
. | . | Lowest (n = 2,892) . | Middle (n = 2,894) . | Upper (n = 2,891) . | P for linear trend . | |||||
Age, mean (SD), y | 42.7 (9.5) | 43.3 (9.5) | 42.7 (9.4) | 42.2 (9.7) | <0.0001 | |||||
BMI, mean (SD), kg/m2 | 25.8 (3.5) | 26.9 (4.2) | 25.5 (3.0) | 25.1 (2.7) | <0.0001 | |||||
Waist circumference, mean (SD), cm | 92.7 (10.1) | 97.5 (10.9) | 92.0 (8.8) | 88.6 (8.3) | <0.0001 | |||||
Percent body fat, mean (SD) | 20.3 (6.2) | 23.6 (5.9) | 20.1 (5.3) | 17.1 (5.5) | <0.0001 | |||||
Maximal METs, mean (SD) | 12.5 (2.5) | 11.5 (2.3) | 12.5 (2.3) | 13.4 (2.4) | <0.0001 | |||||
Treadmill time, mean (SD), min | 19.7 (4.9) | 17.7 (4.8) | 19.7 (4.6) | 21.6 (4.5) | <0.0001 | |||||
Bench press, mean (SD) | ||||||||||
kg | 71.5 (17.4) | 61.6 (12.1) | 69.6 (12.6) | 83.3 (19.0) | <0.0001 | |||||
kg/kg of body weight | 0.9 (0.2) | 0.7 (0.1) | 0.9 (0.1) | 1.1 (0.2) | <0.0001 | |||||
Leg press, mean (SD) | ||||||||||
kg | 136.7 (27.0) | 124.8 (24.7) | 135.5 (23.4) | 149.9 (26.5) | <0.0001 | |||||
kg/kg of body weight | 1.7 (0.3) | 1.4 (0.2) | 1.7 (0.2) | 1.9 (0.3) | <0.0001 | |||||
Lipids, mean (SD), mg/dL | ||||||||||
Total cholesterol | 211 (44) | 214 (41) | 212 (51) | 207 (40) | <0.0001 | |||||
High-density lipoprotein cholesterol | 46 (12) | 45 (12) | 46 (12) | 47 (12) | <0.0001 | |||||
Triglycerides | 130 (106) | 142 (105) | 131 (123) | 117 (85) | <0.0001 | |||||
Fasting blood glucose, mean (SD), mg/dL | 100 (14) | 101 (17) | 99 (13) | 98 (11) | <0.0001 | |||||
Blood pressure, mean (SD), mm Hg | ||||||||||
Systolic | 119 (13) | 120 (13) | 118 (12) | 119 (13) | <0.0001 | |||||
Diastolic | 79 (9) | 80 (9) | 79 (9) | 79 (9) | <0.0001 | |||||
Current smoker, n (%) | 1,313 (15.1) | 492 (17.0) | 455 (15.7) | 366 (12.7) | <0.0001 | |||||
Alcohol intake (≥5 drinks/wk), n (%) | 4,300 (49.6) | 1,431 (49.5) | 1,446 (50.0) | 1,423 (49.2) | 0.84 | |||||
Sedentary*, n (%) | 1,725 (19.9) | 746 (25.8) | 574 (19.8) | 405 (14.0) | <0.0001 | |||||
Baseline medical conditions,† n (%) | ||||||||||
Hypercholesterolemia | 1,875 (21.6) | 687 (23.8) | 632 (21.8) | 556 (19.2) | <0.0001 | |||||
Diabetes mellitus | 208 (2.4) | 100 (3.5) | 49 (1.7) | 59 (2.0) | 0.0005 | |||||
Hypertension | 2,166 (25.0) | 848 (29.3) | 688 (23.8) | 630 (21.8) | <0.0001 | |||||
Cardiovascular disease | 111 (1.3) | 49 (1.7) | 33 (1.1) | 29 (1.0) | 0.02 |
Abbreviations: MET, maximal metabolic equivalents achieved during the treadmill test; kg, kilograms.
Participants were defined as sedentary if they reported no leisure-time physical activity in the 3 mo before baseline examination.
Defined as the presence of hypercholesterolemia [history of physician-diagnosed high cholesterol level or measured fasting total cholesterol level ≥240 mg/dL (6.20 mmol/L)] or diabetes [history of physician diagnosis, use of insulin, or measured fasting glucose level ≥126 mg/dL (7.0 mmol/L), or self-reported diabetes]; or hypertension (history of physician diagnosis or resting systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg).
The death rates per 10,000 person-years, HRs, and 95% CIs for muscular strength and cancer mortality and for adiposity exposures and cancer mortality are shown in Tables 2 and 3, respectively. The cancer mortality rates were 1.59 (17.5/11.0) and 1.70 (17.5/10.3) times greater for those in the lowest third of muscular strength than for those in the middle and upper third of muscular strength, respectively. After adjusting for age, examination year, smoking status, alcohol intake, and baseline medical conditions (Table 2), HRs of cancer mortality across incremental thirds of muscular strength were 1.00, 0.65, and 0.61 (P = 0.003 for linear trend). Further adjustment for BMI, percent body fat, waist circumference, or cardiorespiratory fitness had little effect on the association (Table 2). The test for nonlinearity was not significant (P = 0.08 for quadratic trend). The HRs of cancer mortality were higher across incremental BMI categories (1.0, 1.17, and 1.71; P = 0.03 for linear trend) in models adjusted for age, examination year, smoking status, alcohol intake, and baseline medical conditions. Likewise, those with higher percent body fat (≥25.0% versus <25.0%) had an increased risk of mortality (HR, 1.45; 95% CI, 1.08-1.95; P = 0.01). There was a suggestion of a 30% increased risk of death among those with abdominal obesity (≤102 cm versus >102 cm; HR, 1.30; 95% CI, 0.93-1.82; P = 0.13). The associations of BMI, percent body fat, or waist circumference with cancer mortality did not persist after further adjustment for muscular strength or cardiorespiratory fitness (all P ≥ 0.1).
Risk of cancer mortality according to thirds of muscular strength, Aerobics Center Longitudinal Study, 1980 to 2003
. | Deaths . | Rate* . | HR (95% CI)† . | HR (95% CI)‡ . | HR (95% CI)§ . | HR (95% CI)∥ . | HR (95% CI)¶ . | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Strength thirds | ||||||||||||||
Lowest | 95 | 17.5 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |||||||
Middle | 60 | 11.0 | 0.65 (0.47-0.90) | 0.67 (0.49-0.93) | 0.67 (0.48-0.94) | 0.69 (0.49-0.96) | 0.69 (0.49-0.95) | |||||||
Upper | 56 | 10.3 | 0.61 (0.44-0.85) | 0.64 (0.46-0.90) | 0.64 (0.44-0.92) | 0.68 (0.48-0.97) | 0.70 (0.49-0.98) | |||||||
P for linear trend | 0.001 | 0.003 | 0.008 | 0.01 | 0.03 | 0.03 |
. | Deaths . | Rate* . | HR (95% CI)† . | HR (95% CI)‡ . | HR (95% CI)§ . | HR (95% CI)∥ . | HR (95% CI)¶ . | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Strength thirds | ||||||||||||||
Lowest | 95 | 17.5 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |||||||
Middle | 60 | 11.0 | 0.65 (0.47-0.90) | 0.67 (0.49-0.93) | 0.67 (0.48-0.94) | 0.69 (0.49-0.96) | 0.69 (0.49-0.95) | |||||||
Upper | 56 | 10.3 | 0.61 (0.44-0.85) | 0.64 (0.46-0.90) | 0.64 (0.44-0.92) | 0.68 (0.48-0.97) | 0.70 (0.49-0.98) | |||||||
P for linear trend | 0.001 | 0.003 | 0.008 | 0.01 | 0.03 | 0.03 |
Age and examination year adjusted death rate per 10,000 person-years.
Adjusted for covariates: age, examination year, smoking status, alcohol intake, and medical conditions (presence or absence of hypertension, diabetes, or hypercholesterolemia).
Adjusted for covariates plus BMI.
Adjusted for covariates plus percent body fat.
Adjusted for covariates plus waist circumference.
Adjusted for covariates plus cardiorespiratory fitness.
Risk of cancer mortality according to clinical cut points of adiposity measures, Aerobics Center Longitudinal Study, 1980-2003
. | Deaths . | Rate* . | HR (95% CI)† . | HR (95% CI)‡ . | HR (95% CI)§ . | |||||
---|---|---|---|---|---|---|---|---|---|---|
BMI (kg/m2) | ||||||||||
18.5-24.9 | 83 | 10.9 | 1.00 | 1.00 | 1.00 | |||||
25.0-29.9 | 100 | 13.4 | 1.17 (0.87-1.57) | 1.12 (0.83-1.51) | 1.05 (0.77-1.43) | |||||
≥30.0 | 28 | 20.1 | 1.71 (1.10-2.66) | 1.51 (0.96-2.37) | 1.34 (0.82-2.20) | |||||
P for linear trend | 0.008 | 0.03 | 0.10 | 0.33 | ||||||
Percent body fat (%) | ||||||||||
<25.0 | 139 | 11.6 | 1.00 | 1.00 | 1.00 | |||||
≥25.0 | 70 | 17.5 | 1.45 (1.08-1.95) | 1.27 (0.93-1.74) | 1.25 (0.90-1.75) | |||||
P for difference | 0.006 | 0.01 | 0.13 | 0.19 | ||||||
Waist circumference (cm) | ||||||||||
≤102.0 | 167 | 12.2 | 1.00 | 1.00 | 1.00 | |||||
>102.0 | 44 | 16.7 | 1.30 (0.93-1.82) | 1.13 (0.80-1.61) | 1.07 (0.74-1.55) | |||||
P for difference | 0.06 | 0.13 | 0.50 | 0.70 |
. | Deaths . | Rate* . | HR (95% CI)† . | HR (95% CI)‡ . | HR (95% CI)§ . | |||||
---|---|---|---|---|---|---|---|---|---|---|
BMI (kg/m2) | ||||||||||
18.5-24.9 | 83 | 10.9 | 1.00 | 1.00 | 1.00 | |||||
25.0-29.9 | 100 | 13.4 | 1.17 (0.87-1.57) | 1.12 (0.83-1.51) | 1.05 (0.77-1.43) | |||||
≥30.0 | 28 | 20.1 | 1.71 (1.10-2.66) | 1.51 (0.96-2.37) | 1.34 (0.82-2.20) | |||||
P for linear trend | 0.008 | 0.03 | 0.10 | 0.33 | ||||||
Percent body fat (%) | ||||||||||
<25.0 | 139 | 11.6 | 1.00 | 1.00 | 1.00 | |||||
≥25.0 | 70 | 17.5 | 1.45 (1.08-1.95) | 1.27 (0.93-1.74) | 1.25 (0.90-1.75) | |||||
P for difference | 0.006 | 0.01 | 0.13 | 0.19 | ||||||
Waist circumference (cm) | ||||||||||
≤102.0 | 167 | 12.2 | 1.00 | 1.00 | 1.00 | |||||
>102.0 | 44 | 16.7 | 1.30 (0.93-1.82) | 1.13 (0.80-1.61) | 1.07 (0.74-1.55) | |||||
P for difference | 0.06 | 0.13 | 0.50 | 0.70 |
Age and examination year adjusted death rate per 10,000 person-years.
Adjusted for covariates: age, examination year, smoking status, alcohol intake, and medical conditions (presence or absence of hypertension, diabetes, or hypercholesterolemia).
Adjusted for covariates plus muscular strength.
Adjusted for covariates plus cardiorespiratory fitness.
We also examined the joint associations of muscular strength and adiposity, and muscular strength and cardiorespiratory fitness with cancer mortality to provide greater clinical meaning for physicians and other health professionals (Fig. 1). There were no significant interactions noted in analyses that included cross-product interaction terms. The likelihood ratio test for interaction was χ2df = 1 = 0.70, P = 0.40, for BMI-strength; χ2df = 1 = 0.51, P = 0.48, for percent body fat-strength; χ2df = 1 = 0.77, P = 0.38, for waist circumference-strength; and χ2df = 1 = 1.74, P = 0.19, for cardiorespiratory fitness strength. Muscular strength was inversely associated with cancer death rates in both normal weight and overweight men (both P < 0.05 for linear trend; Fig. 1A), in those of high percent body fat (P = 0.03 for linear trend; Fig. 1B), in those of normal waist circumference (P = 0.002 for linear trend; Fig. 1C), and in those with high levels of cardiorespiratory fitness (P = 0.008 for linear trend; Fig. 1D).
Joint association of muscular strength and BMI (A), percent body fat (B), waist circumference (C), and cardiorespiratory fitness (D) with the age- and examination year–adjusted rates of cancer mortality, Aerobics Center Longitudinal Study, 1980 to 2003. Error bars, SE. Likelihood ratio test for interaction, χ2df = 1 = 0.70, P = 0.40, for BMI-strength; χ2df = 1 = 0.51, P = 0.48, for percent body fat-strength; χ2df = 1 = 0.77, P = 0.38, for waist circumference-strength; and χ2df = 1 = 1.74, P = 0.19, for cardiorespiratory fitness-strength. Black bars, lowest third; gray bars, middle third; white bars, upper third of baseline muscular strength. Numbers under the bar, sample size (deaths from cancer).
Joint association of muscular strength and BMI (A), percent body fat (B), waist circumference (C), and cardiorespiratory fitness (D) with the age- and examination year–adjusted rates of cancer mortality, Aerobics Center Longitudinal Study, 1980 to 2003. Error bars, SE. Likelihood ratio test for interaction, χ2df = 1 = 0.70, P = 0.40, for BMI-strength; χ2df = 1 = 0.51, P = 0.48, for percent body fat-strength; χ2df = 1 = 0.77, P = 0.38, for waist circumference-strength; and χ2df = 1 = 1.74, P = 0.19, for cardiorespiratory fitness-strength. Black bars, lowest third; gray bars, middle third; white bars, upper third of baseline muscular strength. Numbers under the bar, sample size (deaths from cancer).
Age and examination year–adjusted cancer mortality rates per 10,000 person-years in normal and overweight individuals were significantly higher among those in the low muscular strength category than among those in the middle and high strength categories (Fig. 1A). Cancer mortality rates were significantly higher among individuals in the low muscular strength category versus those who were in the middle- and high-strength category within the abnormal percent body fat group (Fig. 1B). The same pattern was observed in the normal percent body fat group; however, the association was only marginally statistically significant (P = 0.08). Finally, as shown in Fig. 1C, cancer mortality rates were significantly higher among individuals with low muscular strength than those who were in the middle- and high-strength categories in the normal waist circumference group, whereas no association between muscular strength and cancer mortality rates was observed in the abdominal obese group (P = 0.77).
We focused primarily on all-cause cancer mortality because of the relatively small number of site-specific cancer deaths across strength levels on our cohort. However, some exploratory analyses were done for the associations between muscular strength and site-specific cancers (Table 4). In the current study, cancers in the digestive system accounted for 31% (n = 65) of total cancer deaths. After adjusting for age and examination year, HR (95% CI) values were 1.00 (reference), 0.37 (0.19-0.70), and 0.49 (0.27-0.87) across incremental thirds of muscular strength, respectively (P = 0.007 for linear trend). The corresponding numbers of deaths were 35, 13, and 17 for the low-, middle-, and high-strength third, respectively. Excluding deaths that occurred during the first 2 years of follow-up did not materially change the results.
Risks of site-specific cancer mortality according to thirds of muscular strength, Aerobics Center Longitudinal Study, 1980-2003
Anatomic site-strength thirds . | Deaths . | HR (95% CI)* . | ||
---|---|---|---|---|
All digestive system† | ||||
Low | 35 | 1.00 | ||
Middle | 13 | 0.37 (0.19-0.70) | ||
High | 17 | 0.49 (0.27-0.87) | ||
P for linear trend | 0.007 | |||
Colorectal | ||||
Low | 11 | 1.00 | ||
Middle | 2 | 0.18 (0.04-0.82) | ||
High | 6 | 0.53 (0.20-1.45) | ||
P for linear trend | 0.16 | |||
Pancreas | ||||
Low | 11 | 1.00 | ||
Middle | 4 | 0.36 (0.11-1.13) | ||
High | 6 | 0.54 (0.20-1.47) | ||
P for linear trend | 0.18 | |||
Lung | ||||
Low | 17 | 1.00 | ||
Middle | 17 | 0.998 (0.51-1.96) | ||
High | 13 | 0.76 (0.37-1.57) | ||
P for linear trend | 0.47 | |||
Prostate | ||||
Low | 3 | 1.00 | ||
Middle | 7 | 2.56 (0.66-9.97) | ||
High | 3 | 1.03 (0.21-5.16) | ||
P for linear trend | 0.96 | |||
Hematopoietic/lymph | ||||
Low | 11 | 1.00 | ||
Middle | 8 | 0.71 (0.28-1.76) | ||
High | 8 | 0.71 (0.28-1.76) | ||
P for linear trend | 0.45 |
Anatomic site-strength thirds . | Deaths . | HR (95% CI)* . | ||
---|---|---|---|---|
All digestive system† | ||||
Low | 35 | 1.00 | ||
Middle | 13 | 0.37 (0.19-0.70) | ||
High | 17 | 0.49 (0.27-0.87) | ||
P for linear trend | 0.007 | |||
Colorectal | ||||
Low | 11 | 1.00 | ||
Middle | 2 | 0.18 (0.04-0.82) | ||
High | 6 | 0.53 (0.20-1.45) | ||
P for linear trend | 0.16 | |||
Pancreas | ||||
Low | 11 | 1.00 | ||
Middle | 4 | 0.36 (0.11-1.13) | ||
High | 6 | 0.54 (0.20-1.47) | ||
P for linear trend | 0.18 | |||
Lung | ||||
Low | 17 | 1.00 | ||
Middle | 17 | 0.998 (0.51-1.96) | ||
High | 13 | 0.76 (0.37-1.57) | ||
P for linear trend | 0.47 | |||
Prostate | ||||
Low | 3 | 1.00 | ||
Middle | 7 | 2.56 (0.66-9.97) | ||
High | 3 | 1.03 (0.21-5.16) | ||
P for linear trend | 0.96 | |||
Hematopoietic/lymph | ||||
Low | 11 | 1.00 | ||
Middle | 8 | 0.71 (0.28-1.76) | ||
High | 8 | 0.71 (0.28-1.76) | ||
P for linear trend | 0.45 |
Adjusted for age and examination year.
Esophagus, n = 7; stomach, n = 10; colon, n = 16; rectum, n = 3; liver, n = 6; pancreas, n = 21; gall bladder, n = 2.
Discussion
There were three main findings from this study: First, muscular strength was significantly and inversely associated with cancer mortality risk in men independent of potential confounders such as age, smoking, alcohol intake, and health status. This association remained significant after further adjustment for measures of overall adiposity (i.e., BMI and percent body fat) and central adiposity (i.e., waist circumference). Additionally, adjusting for cardiorespiratory fitness had little effect on the associations. Second, BMI, percent body fat, and waist circumference were positively associated with rates of cancer mortality. However, the associations did not persist after adjusting for muscular strength or cardiorespiratory fitness. Third, analyses on the joint associations between muscular strength and adiposity revealed that cancer mortality rates in men with low levels of muscular strength (lowest third) and with high levels of adiposity were 40% to 50% higher (all P < 0.01) than the rates in the group of obese men with at least moderate (middle third) levels of muscular strength.
Higher levels of muscular strength were inversely associated with cancer mortality in both normal weight and overweight men, in those who have excessive percent body fat, in those with a normal waist circumference, and in those with high levels of cardiorespiratory fitness (Fig. 1). Men with abdominal obesity (waist circumference >102 cm) and low levels of muscular strength were not at higher risk for cancer mortality when compared with those with high levels of muscular strength and with abdominal obesity. The group of men with abdominal obesity as well as those with high levels of cardiorespiratory fitness had small sample sizes and fewer deaths (Fig. 1C), resulting in a lack of statistical power. Therefore, these results should be confirmed in studies with a larger number of outcomes.
Taken together, these findings indicate that having at least moderate age-adjusted levels of muscular strength may counteract the deleterious consequences attributed to adiposity. To place our findings into a more public health perspective, the recommendation is to avoid falling into the low age-adjusted muscular strength category. Efforts should then focus not only on reducing levels of adiposity but also on increasing the muscular strength level.
Our findings are in accordance with those published by Gale et al. (15) but not with others (14, 16, 17). These studies measured muscular strength in only one small muscle group (handgrip strength), which may have masked the strength-cancer association. Additionally, they did not adjust for cardiorespiratory fitness. A thorough assessment of muscular strength should include testing of several major muscle groups. In addition, previous studies were either short-term follow-ups (5-6 years; refs. 14, 16) or included only older adults (≥65 years; refs. 15, 16). Our study group is unique in that we standardized the measures of muscular strength by testing the major muscle groups of the upper and lower body. Also, we included measures of adiposity and cardiorespiratory fitness in a large cohort of men ages 20 to 82 years, including an extensive follow-up, and with a comprehensive baseline clinical examination.
Higher levels of cardiorespiratory fitness are strongly associated with lower risk of cancer mortality in men and women, young or older people, and in diabetic or nondiabetic persons, independently of their weight status and tobacco use (18-25). It is worth noting that in the present study, muscular strength and cardiorespiratory fitness were moderately correlated (age-adjusted partial r = 0.33). This suggests that the association between muscular strength and cancer mortality risk works, at least partially, through different mechanisms than those associated with the salutatory effects attributed to cardiorespiratory fitness. The apparent protective effect of muscular strength against cancer is likely to be due to a consequence of regular physical exercise, specifically resistance exercise. Muscular strength has a genetic component, yet there is convincing evidence that resistance-type physical activities are major determinants of muscular strength (11). We have observed a strong and direct association between self-reported participation in resistance exercises and muscular strength in men from the ACLS (41); that is, the higher the participation in resistance exercise, the higher the muscular strength. This suggests that the muscular strength measurements obtained in the present study provide an adequate representation of the physical activities that involve resistance, such as daily work, lifting, or carrying things, etc.
There are plausible biological mechanisms that may explain the lower risk of cancer mortality seen in men with higher levels of muscular strength, such as regulation in the metabolism of insulin, and insulin-like growth factors (IGF), which have been linked to increased risk of several types of cancer (43, 44). There is compelling evidence that physical activity improves insulin sensitivity and increases glucose uptake by skeletal muscle, even in persons with type 2 diabetes mellitus (45). Intervention studies have shown that resistance training improves both insulin sensitivity and glycemic control (46-48). A decrease in the levels of IGF-I has been observed after a resistance training period, concurrently with an increase in IGF binding protein-3 (49). IGF binding protein-3 binds to circulating IGF in the blood and decreases its ability to nurture potential cancer sites (50). Other potential mechanisms associated with higher levels of muscular strength include reduced exposure to systemic inflammation (51, 52), sex hormones (53, 54), improved antioxidant defense (55, 56) and immune function (57), and reduced overall and central adiposity (11).
Resistance exercise is an important complement for weight control, mainly due to the increases in metabolically active muscle mass (9). Resting energy expenditure is the largest component of total energy expenditure, especially when physically inactive. The energy expenditure related to muscle metabolism is the only component of resting energy expenditure that varies considerably (9). Therefore, the maintenance of a large muscle mass and consequent muscle protein turnover across a relatively long period of time may contribute to the prevention of obesity. Consequently, it is presumable that when sustained over time, resistance exercise training should help prevent increases in body fat (11). This fact has important public health implications given that the prevalence of overweight and obesity exceeds 70% in the U.S. men (58) and 65% of men from the United Kingdom (59). Moreover, the prevalence of these conditions is expected to increase, in the United Kingdom, for example, to 75% of men by 2010 (59).
The observed positive association of BMI, percent body fat, and waist circumference with cancer mortality confirm the results of numerous studies reporting that overweight and obesity are associated with increased risk of common and less common cancers (3-5). That the associations of BMI, percent body fat, and waist circumference with cancer mortality did not persist after adjusting for muscular strength or cardiorespiratory fitness is noteworthy. In addition, the observation that cancer mortality rates of obese men with at least moderate levels of muscular strength are 40% to 50% lower than their obese peers in the lowest strength third have important public health implications and should inform the exploration of biological mechanisms that link obesity and muscular strength with cancer. These findings acquire special relevance because cigarette smoking (which is the largest cause of cancers in developed countries) is decreasing, and therefore adiposity and sedentariness may become the dominant lifestyle factors contributing to cancer occurrence in such countries (5). The key role of muscle mass in a number of metabolic processes and in the prevention of many common pathologic conditions and chronic diseases has been highlighted (9). Therefore, it is reasonable to hypothesize that increased muscle mass in those men with higher levels of muscular strength may partially explain their reduced cancer mortality rates compared with those men with lower strength levels.
The limitations of the current study include the fact that participants were predominantly male, white, well educated, and from middle to upper socioeconomic status. This may limit the ability to generalize the study results but does not affect the internal validity of the study. Although cancer death rates seem to vary by both level of education and by race (60), there is little reason to assume that the benefits of muscular strength would be different in other racial/ethnic or socioeconomic groups. Due to a limited number of women, who contributed relatively few cancer deaths to the current study, we were unable to perform a meaningful parallel analysis on women. Therefore, women were not included in this study.
None of the participants reported family history of cancer, which might be another limitation of the ACLS due to self-selection bias. In fact, only 1.16% of men in the entire cohort reported a family history of cancer. Therefore, our cohort might be considered to be at the positive end of the health spectrum, that is, a group with the greatest chance of cancer survival. That we saw a significant association between muscular strength and cancer mortality is then remarkable. These findings indicate that even in men with the best chance of cancer survival, having higher levels of muscular strength is associated with lower risk of cancer mortality compared with those men with low levels of strength. We identified an inverse association between muscular strength and cancers in the digestive system, yet the findings should be interpreted cautiously because of the small number of deaths in our cohort. The small number of site-specific digestive system cancers or other site-specific cancers also precluded us performing further analyses.
No detailed information about medication use or dietary habits was available, which may have biased the results through residual confounding. However, given that adjusting for BMI, percent body fat, or waist circumference did not diminish the strength-cancer mortality association, it is unlikely that accounting for dietary behaviors would have a major influence on the results.
In this cohort, we had only a single baseline assessment of muscular strength, adiposity measurements, and cardiorespiratory fitness; thus, whether changes in any of these variables occurred during follow-up, and whether this may have influenced the study results, is not known. It is important to bear in mind that, aside from its association with lifestyle-related variables, at present it is difficult to know how muscular fitness functions with respect to the molecular/genetic mechanisms involved in the carcinogenesis and tumor growth and development.
In conclusion, the present study showed that higher levels of muscular strength were associated with lower cancer mortality risk in men, independent of clinically established measures of overall and central adiposity, cardiorespiratory fitness, and other potential confounders. Mortality rates were lower for men with moderate/high muscular strength compared with individuals with low strength. Although each adiposity measure was positively associated with cancer mortality, the association was eliminated after adjusting for either muscular strength or cardiorespiratory fitness. These findings suggest that attaining a moderate to high level of muscular strength may attenuate some of the cancer mortality risks associated with increased adiposity. Maintaining a healthy weight should continue to be a cornerstone in the prevention of chronic diseases and premature death. However, in the light of the results obtained in the present study and in other studies, it is equally important to maintain healthy muscular strength levels, and, most importantly, to prevent falling into the lower strength categories.
It is biologically plausible to reduce cancer mortality death rates among men by promoting regular resistance training involving the major muscle groups of the upper and lower extremities at least 2 days per week (10-13). Resistance and aerobic exercise should complement each other. The recommendation for moderate to vigorous physical activity and resistance training are supported by the current research showing a reduction in all-cause and cancer mortality associated with increased cardiorespiratory fitness, muscular strength, or both.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Grant support: NIH grants AG06945 and HL62508; The Spanish Ministry of Education (EX-2007-1124); the Swedish Council for Working Life and Social Research, the European Union, in the framework of the Public Health Programme (ALPHA project, Ref: 2006120); the American Heart Association Predoctoral Fellowship; and the American College of Sports Medicine Paffenbarger-Blair Fund for Epidemiological Research on Physical Activity.
Acknowledgments
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
We thank the doctors and technicians at The Cooper Clinic who collected the baseline data and staff at the Cooper Institute for data entry and data management.